Mammoth Biosciences Stock

mammoth.bioHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $257.38MM

Mammoth Biosciences is a biotechnology company that, through the discovery and development of novel CRISPR systems, is enabling the full potential of its platform to improve lives by reading and writing the code of life. The company was founded by Trevor Martin Ph.D., Janice Chen Ph.D., Lucas Harrington, and Jennifer Doudna Ph.D. in 2017 and is headquartered in Brisbane, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for Mammoth Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Mammoth Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Mammoth Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Trevor Martin Ph.D
Co-Founder & Chief Executive Officer
Lucas Harrington
Co-Founder & Chief Scientific Officer
Jennifer Doudna Ph.D
Co-Founder & Chairman of Scientific Advisory Board
Janice Chen Ph.D
Co-Founder & Chief Technology Officer
Ted Tisch
Chief Agility Officer

Board Members

Dean Minor MD
Board Member
Maneesh Jain Ph.D
Board Member
Ursheet Parikh
Mayfield (Private Equity)
Victor Tong Jr.
Decheng Capital

Frequently Asked Questions About Mammoth Biosciences’ Stock

plusminus
Can you buy Mammoth Biosciences’ stock?
Mammoth Biosciences is not publicly traded on NYSE or NASDAQ in the U.S. To buy Mammoth Biosciences’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Mammoth Biosciences’ stock?
Yes, you can sell stock of a private company like Mammoth Biosciences. Forge can help you sell your Mammoth Biosciences stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Mammoth Biosciences’ stock price?
Mammoth Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Mammoth Biosciences’ private market stock price with Forge Data.
plusminus
What is Mammoth Biosciences’ stock ticker symbol?
Mammoth Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Mammoth Biosciences Announces Appointment of Phil Tinmouth, Siang Chin to Key Leadership Roles
Mammoth Biosciences, Inc., a biotechnology company building the next generation of CRISPR products with a mission to cure and detect diseases, today announced the appointment of Phil Tinmouth as Chief Business Officer and Siang Chin as General Counsel.
CRISPR biotech company Mammoth Biosciences gains unicorn status
San Francisco-based Mammoth Biosciences has closed on a $150 million Series D led by Redmile Group, which now values the CRISPR biotech company at $1 billion, making it a new addition to the Crunchbase Unicorn Board.
Mammoth Biosciences’s CRISPR-based COVID-19 test receives NIH funding through RADx program – TechCrunch
CRISPR tech startup Mammoth Biosciences is among the companies that revealed backing from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) program on Friday. Mammoth received a contract to scale up its CRISPR-based SARS-CoV-2 diagnostic test in order to help address …
Updated on: Feb 28, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.